Erich Spangenberg Named CEO of Spectral AI’s IP-Focused Subsidiary

Spectral AI Inc. has appointed Erich Spangenberg as CEO of its health care IP-focused subsidiary, Spectral IP.
 
“Spectral AI is fortunate that our largest shareholder, Erich Spangenberg, has agreed to assume the CEO role at Spectral IP. Erich has consistently been recognized for his track record in global IP investment, monetization, enforcement, acquisition, and licensing,” Spectral AI CEO Pete Carlson said. “Our goal with Spectral IP is to create a healthcare IP-focused enterprise that potentially provides additional IP protection for the company and unlocks additional value for MDAI shareholders while requiring limited company management resources and no additional capital . As CEO of Spectral IP, Erich will report to me and to our board as he prepares Spectral IP for a potential spinoff.”
  
Spangenberg is the founder and co-managing partner at Sauvegarder Investment Management (SIM), a multi-strategy investment firm dedicated to IP-related financing and investment opportunities. SIM invests across IP as an asset class and across jurisdictions, primarily focusing on the United States, Europe, and Asia. He is recognized by various publications as one of the world’s top-50 IP strategists, credited with being one of the people who is changing the way people think about and use patents. After an early career that included partnership in a leading global law firm, investment banker, and business executive, Spangenberg in 2003 focused his business efforts on IP investment opportunities.

Spangenberg has been involved as a principal in more than 1,000 IP licensing transactions that generated over $500 million in revenue and as a principal and advisor on over $2 billion of patent financing and technology acquisition transactions.
 
“I believe Spectral IP represents a significant opportunity to deliver additional value to Spectral AI shareholders. One of my affiliates has provided Spectral IP with $1 million of debt capital,” Spangenberg stated. “I believe I can secure an additional $5 million to $10 million of equity capital for our new entity, which I believe will be more than adequate to fund Spectral IP for approximately one year after a possible spinoff transaction is completed. As the largest shareholder and investor in Spectral AI, I plan to utilize my global network and my decades of IP experience to focus on healthcare IP-related investments and acquisitions. These IP-related investments and acquisitions will include licensing, sales, royalty finance, credit-related and other diverse financial opportunities within the IP class.”

Spectral AI plans to form a special board committee to evaluate and oversee a possible partial spinoff transaction of Spectral IP shares.
 
Spectral AI Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The company is working to improve wound care management with its DeepView System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention.